Dr. Mok Discusses Developing Lung Cancer Treatments

Tony S.K. Mok, BMSc, MD, FRCPC
Published Online: Thursday, September 12, 2013
Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.

Mok says in order to move forward, multiple parties such as pharmaceutical industries, academic institutions, and the FDA have to make changes.

As an example, Mok says, the FDA should look into how it registers drugs because the current practice of demanding a companion diagnostic may actually be slowing down the development of the drug.

Mok also suggests making changes to the pharmaceutical industry by having external tribunals advise pharmaceutical companies on which drugs to develop rather than wasting money by trying to develop many drugs.

Online CME Activities
Free CME from PER
Recap of SABCS 2014: Changes for Today and Hope for Tomorrow
Cancer Summaries and Commentaries: Updates From San Francisco in Multiple Myeloma
10th International Symposium on Ovarian Cancer and Gynecologic Malignancies® Medical Crossfire®
Community Practice Connections: 12th Annual International Congress on Targeted Therapies in Cancer®
More Reading
$auto_registration$